---
date: '2024-03-08'
modified_time: 2024-03-08 19:12:21-05:00
published_time: 2024-03-08 19:12:20-05:00
source_url: https://www.whitehouse.gov/briefing-room/statements-releases/2024/03/08/readout-of-white-house-meeting-with-rsv-immunization-manufacturers-2/
tags: statements-releases
title: "Readout of White\_House Meeting with RSV Immunization Manufacturers"
---
 
This week, senior Biden-Harris Administration officials again met with
manufacturers of RSV immunizations including Sanofi and AstraZeneca and
their partners. During the meeting, manufacturers discussed recent
studies showing significant decreases in hospitalization rates among
infants who received Nirsevimab. Senior administration officials and
manufacturers also discussed the processes for continuing to update data
on the safety and effectiveness of this immunization, as well as efforts
to ensure continued availability of infant RSV immunizations in the US
for the remainder of this season. At the urging of the Administration
and in response to unprecedented requests for these immunizations, RSV
manufacturers made 307,000
[additional](https://www.whitehouse.gov/briefing-room/statements-releases/2023/12/14/readout-of-latest-white-house-meeting-with-rsv-immunization-manufacturers/)
[doses](https://www.cdc.gov/media/releases/2023/p1116-rsv-doses.html)
available to families, increasing supply and expediting availability.
Manufacturers also described their work to ensure availability of RSV
doses for infants ahead of the 2024-2025 respiratory season.

\###
